Why significant? that represents close to $2B in MKT CAP for BIIB.
In relationship to ISIS that almost 2X our current MKT CAP
so what impact will ISIS franchise have on its future MKT CAP as it moves their drug into development from pre-clinical??? Could be in P3 with a fast track drug designation in about 4 years or sooner with a P2/P3 designed trial.
ISIS antisense PLATFORM is very undervalued at $10 and change.